Literature DB >> 10195646

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

E N Jonsson1, M O Karlsson.   

Abstract

The building of population pharmacokinetic/pharmacodynamic (PK/PD) models is a time consuming and complicated task. This is partly due the lack of specialized tools for the visualization and exploration requirements of this type of analysis. In this paper we present Xpose, a model building aid for population PK/PD analysis using NONMEM, which simplifies the task of producing documentation, data set checkout plots, goodness of fit plots and graphical model comparison. It also facilitates covariate model building by the use of stepwise generalized additive modeling (GAM), bootstrap of the GAM analyses and tree based modeling. The plots and analyses are presented in the form of a text based menu system and the only thing the user has to do is to make NONMEM produce one or more table files named in a specific way.

Entities:  

Mesh:

Year:  1999        PMID: 10195646     DOI: 10.1016/s0169-2607(98)00067-4

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  454 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

Authors:  S Sadray; E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

Review 3.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

4.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

6.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

7.  Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Authors:  Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

8.  Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Authors:  Marcus A Björnsson; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

9.  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Authors:  Gautam Baheti; Jennifer R King; Edward P Acosta; Courtney V Fletcher
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

10.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.